HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Asensus Surgical (AMEX:ASXC) with a Buy and maintains $3 price target.
Cellectar Biosciences Granted U.S. Patent #11,439,709 Phospholipid Ether Analogs as Cancer-targeting Drug Vehicles
https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=6652&f=G&l=50&d=PTXT&p=134&S1=20220913&OS=20220913&RS=20220913
